Aryl Sulfonohydrazides

Anne K. Voss; Jonathan B. Baell; Nghi Nguyen; David Leaver; Benjamin Cleary; H. Rachel Lagiakos; Bilal N. Sheikh; Timothy Thomas

Aryl Sulfonohydrazides

Anne K. Voss (Inventor), Jonathan B. Baell (Inventor), Nghi Nguyen (Inventor), David Leaver (Inventor), Benjamin Cleary (Inventor), H. Rachel Lagiakos (Inventor), Bilal N. Sheikh (Inventor), Timothy Thomas (Inventor)

Research output: Patent

Abstract

Compound of formula (I) wherein A is selected from (i), where RF1 is H or F; (ii); (iii) a N-containing Cll heteroaryl group; and B is (B), where X1 is either CR^F2 or N, where R^F2 is H or F; X² is either CR³ or N, where R³ is selected from H, Me, Cl, F OMe; X³ is either CH or N; X⁴ is either CR^F3 or N, where R^F3 is H or F; where only one or two of X¹, X², X³ and X⁴ may be N; and R⁴ is selected from I, optionally substituted phenyl, optionally substituted C_5-6 heteroaryl; optionally substituted C_1-6 alkyl and optionally substituted C_1-6 alkoxy, which are useful in the treatment of a condition ameliorated by the inhibition of MOZ.

Original language	English
Patent number	WO2016198507
IPC	A61K31/145 (2006.01),A61K 31/341 (2006.01),A61K31/38 (2006.01),A61K31/395 (2006.01),C07D 213/87 (2006.01),C07D 231/12 (2006.01),C07D 231/16 (2006.01),C07D 333/24 (2006.01),C07C 311/49 (2006.01),C07D 237/08 (2006.01),C07D 249/06 (2006.01),C07D 271/06 (2006.01),C07D 271/10 (2006.01),C07D 277/30 (2006.01),C07D 213/54 (2006.01),C07D 307/54 (2006.01),A61P 35/02 (2006.01)
Priority date	09/06/15
Filing date	09/06/16
Publication status	Published - 15 Dec 2016
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@misc{bcbac683eff240489cb15e90d6ac4b17,

title = "Aryl Sulfonohydrazides",

abstract = "Compound of formula (I) wherein A is selected from (i), where RF1 is H or F; (ii); (iii) a N-containing Cll heteroaryl group; and B is (B), where X1 is either CRF2 or N, where RF2 is H or F; X2 is either CR3 or N, where R3 is selected from H, Me, Cl, F OMe; X3 is either CH or N; X4 is either CRF3 or N, where RF3 is H or F; where only one or two of X1, X2, X3 and X4 may be N; and R4 is selected from I, optionally substituted phenyl, optionally substituted C5-6 heteroaryl; optionally substituted C1-6 alkyl and optionally substituted C1-6 alkoxy, which are useful in the treatment of a condition ameliorated by the inhibition of MOZ.",

author = "Voss, {Anne K.} and Baell, {Jonathan B.} and Nghi Nguyen and David Leaver and Benjamin Cleary and Lagiakos, {H. Rachel} and Sheikh, {Bilal N.} and Timothy Thomas",

year = "2016",

month = dec,

day = "15",

language = "English",

type = "Patent",

note = "WO2016198507; A61K31/145 (2006.01),A61K 31/341 (2006.01),A61K31/38 (2006.01),A61K31/395 (2006.01),C07D 213/87 (2006.01),C07D 231/12 (2006.01),C07D 231/16 (2006.01),C07D 333/24 (2006.01),C07C 311/49 (2006.01),C07D 237/08 (2006.01),C07D 249/06 (2006.01),C07D 271/06 (2006.01),C07D 271/10 (2006.01),C07D 277/30 (2006.01),C07D 213/54 (2006.01),C07D 307/54 (2006.01),A61P 35/02 (2006.01)",

}

TY - PAT

T1 - Aryl Sulfonohydrazides

AU - Voss, Anne K.

AU - Baell, Jonathan B.

AU - Nguyen, Nghi

AU - Leaver, David

AU - Cleary, Benjamin

AU - Lagiakos, H. Rachel

AU - Sheikh, Bilal N.

AU - Thomas, Timothy

PY - 2016/12/15

Y1 - 2016/12/15

N2 - Compound of formula (I) wherein A is selected from (i), where RF1 is H or F; (ii); (iii) a N-containing Cll heteroaryl group; and B is (B), where X1 is either CRF2 or N, where RF2 is H or F; X2 is either CR3 or N, where R3 is selected from H, Me, Cl, F OMe; X3 is either CH or N; X4 is either CRF3 or N, where RF3 is H or F; where only one or two of X1, X2, X3 and X4 may be N; and R4 is selected from I, optionally substituted phenyl, optionally substituted C5-6 heteroaryl; optionally substituted C1-6 alkyl and optionally substituted C1-6 alkoxy, which are useful in the treatment of a condition ameliorated by the inhibition of MOZ.

AB - Compound of formula (I) wherein A is selected from (i), where RF1 is H or F; (ii); (iii) a N-containing Cll heteroaryl group; and B is (B), where X1 is either CRF2 or N, where RF2 is H or F; X2 is either CR3 or N, where R3 is selected from H, Me, Cl, F OMe; X3 is either CH or N; X4 is either CRF3 or N, where RF3 is H or F; where only one or two of X1, X2, X3 and X4 may be N; and R4 is selected from I, optionally substituted phenyl, optionally substituted C5-6 heteroaryl; optionally substituted C1-6 alkyl and optionally substituted C1-6 alkoxy, which are useful in the treatment of a condition ameliorated by the inhibition of MOZ.

M3 - Patent

M1 - WO2016198507

Y2 - 2016/06/09

ER -

Aryl Sulfonohydrazides

Abstract

UN SDGs

Fingerprint

Cite this